Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency

Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency

Abstract Background The experience from clinical trials indicates that anti-Aβ immunotherapy could be effective in early/pre-clinical stages of AD, whereas at the late stages promoting the clearing of Aβ alone may be insufficient to halt the disease progression. At the same time, pathological tau co...

Full description

Bibliographic Details
Main Authors: Michael G. Agadjanyan, Karen Zagorski, Irina Petrushina, Hayk Davtyan, Konstantin Kazarian, Maxim Antonenko, Joy Davis, Charles Bon, Mathew Blurton-Jones, David H. Cribbs, Anahit Ghochikyan
Format: Article
Language:English
Published: BMC 2017-05-01
Series:Molecular Neurodegeneration
Subjects:
Alzheimer’s disease
Tauopathy
Phosphatase activation domain
Immunotherapy
Monoclonal antibody
Humanization
Online Access:http://link.springer.com/article/10.1186/s13024-017-0172-1

Internet

http://link.springer.com/article/10.1186/s13024-017-0172-1

Similar Items